Actively Recruiting
Biomarkers of Brain Injury in Children With Brain Tumors
Led by Uppsala University · Updated on 2026-02-02
560
Participants Needed
1
Research Sites
543 weeks
Total Duration
On this page
Sponsors
U
Uppsala University
Lead Sponsor
R
Region Blekinge
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this observational study is to identify biomarkers of treatment-induced brain injury in children treated for primary brain tumors. The main question it aims to answer is: Can investigators identify sensitive plasma biomarker(s) of treatment-induced brain injury in children with primary brain tumors? Researchers will compare results between different treatment modalities (surgery, chemotherapy, radiation versus radiation-naive) and a healthy age- and sex-matched control population, to identify treatment-specific biomarkers. Participants will provide plasma samples at the following time points: before surgery, 1-2 weeks after surgery, as well as at 3-, 6-, 12-, 18-, 24-, and 36 months after surgery. Participants who receive radiation treatment will also provide plasma samples before and during treatment (approximately every 2 weeks). Where possible, plasma samples are also collected before the start of any new treatment (e.g., chemotherapy). Healthy controls will provide samples once.
CONDITIONS
Official Title
Biomarkers of Brain Injury in Children With Brain Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 0-17 years old
- Diagnosed with primary brain tumor through surgery, biopsy, or other diagnostic methods at Uppsala University Hospital or another university hospital in Sweden
- Referred for radiotherapy at Skandion Clinic in Uppsala and/or local hospital (with or without other cancer treatments) (Group A)
- Not referred to radiotherapy and treated with or without other cancer treatments (Group B)
- Healthy children aged 0-17 years old at time of recruitment (Group C)
You will not qualify if you...
- Diagnosed with a tumor only in the spinal cord (Groups A and B)
- Diagnosed with a tumor considered palliative at diagnosis, such as diffuse intrinsic pontine glioma (Groups A and B)
- Diagnosis of chronic disease requiring continuous medication (Group C)
- Unable to provide informed consent due to language difficulties (all groups)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Uppsala University
Uppsala, Sweden
Actively Recruiting
Research Team
C
Christoffer Ehrstedt, MD, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here